Gain Therapeutics, Inc. (GANX)
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
GANX Insider Trading Activity
GANX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $200,924 | 4 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Riley Jeffrey Scott | director | 1 | $115,770 | 0 | $0 | $115,770 |
| Islam Khalid | Executive Chairman | 1 | $49,940 | 0 | $0 | $49,940 |
| RICHMAN ERIC I | director | 1 | $20,670 | 0 | $0 | $20,670 |
| Mack Gene | CFO and Interim CEO | 1 | $14,544 | 0 | $0 | $14,544 |
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Insider Activity of Gain Therapeutics, Inc.
Over the last 12 months, insiders at Gain Therapeutics, Inc. have bought $200,924 and sold $0 worth of Gain Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Gain Therapeutics, Inc. have bought $93,446 and sold $5,057 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Riley Jeffrey Scott (director) — $115,770. Islam Khalid (Executive Chairman) — $49,940. RICHMAN ERIC I (director) — $20,670.
The last purchase of 50,000 shares for transaction amount of $49,940 was made by Islam Khalid (Executive Chairman) on 2024‑08‑09.
List of Insider Buy and Sell Transactions, Gain Therapeutics, Inc.
| 2024-08-09 | Islam Khalid | Executive Chairman | 50,000 0.2022% | $1.00 | $49,940 | +100.73% | ||
| 2024-08-09 | Mack Gene | CFO and Interim CEO | 14,400 0.0589% | $1.01 | $14,544 | +100.73% | ||
| 2024-07-01 | RICHMAN ERIC I | director | 17,000 0.0902% | $1.22 | $20,670 | +62.50% | ||
| 2024-03-28 | Riley Jeffrey Scott | director | 30,000 0.1501% | $3.86 | $115,770 | -45.09% | ||
| 2023-12-21 | Sale | Alder Matthias | Chief Executive Officer | 206 0.0014% | $2.46 | $507 | -6.00% | |
| 2023-12-07 | Sale | Alder Matthias | Chief Executive Officer | 1,820 0.0122% | $2.50 | $4,550 | -2.78% | |
| 2022-05-25 | RICHMAN ERIC I | CHIEF EXECUTIVE OFFICER | 2,482 0.0203% | $2.58 | $6,404 | +43.21% | ||
| 2022-05-19 | RICHMAN ERIC I | CHIEF EXECUTIVE OFFICER | 9,256 0.0816% | $2.83 | $26,194 | +39.63% | ||
| 2022-05-19 | Calabrese Salvatore | CHIEF FINANCIAL OFFICER | 3,000 0.0252% | $2.70 | $8,100 | +39.63% | ||
| 2021-08-16 | RICHMAN ERIC I | Chief Executive Officer | 4,922 0.042% | $7.87 | $38,716 | -45.68% |
Insider Historical Profitability
| RICHMAN ERIC I | director | 289629 1.0919% | $660,354.12 | 4 | 0 | +12.38% |
| Islam Khalid | Executive Chairman | 50000 0.1885% | $114,000.00 | 1 | 0 | |
| Riley Jeffrey Scott | director | 30000 0.1131% | $68,400.00 | 1 | 0 | |
| Mack Gene | CFO and Interim CEO | 14400 0.0543% | $32,832.00 | 1 | 0 | |
| Alder Matthias | Chief Executive Officer | 5286 0.0199% | $12,052.08 | 0 | 2 | |
| Calabrese Salvatore | CHIEF FINANCIAL OFFICER | 3000 0.0113% | $6,840.00 | 1 | 0 | +39.63% |
Historical Insider Profitability vs. Competitors
$2,942,496 | 100 | 17.32% | $64.28M | |
$6,787,959 | 35 | 49.84% | $63.1M | |
$459,011,221 | 33 | 33.04% | $55.85M | |
$18,752,549 | 33 | -28.34% | $52.48M | |
$46,744,488 | 32 | -8.46% | $64.03M | |
$144,247,213 | 29 | 10.15% | $62.38M | |
$2,239,226 | 28 | 3.41% | $60.28M | |
$26,736,140 | 20 | -18.64% | $58.86M | |
$47,863,113 | 17 | -22.07% | $51.99M | |
$28,281,140 | 14 | 18.42% | $63.91M | |
$91,549,696 | 8 | -6.55% | $60.79M | |
$478,647 | 7 | 69.41% | $54.41M | |
$17,872,846 | 6 | -27.97% | $54.35M | |
$119,593,679 | 6 | -21.91% | $56.81M | |
$106,599,960 | 6 | -7.63% | $62.84M | |
$20,729,984 | 5 | 51.71% | $62.83M | |
Gain Therapeutics, Inc. (GANX) | $79,414 | 4 | 19.20% | $60.48M |
$105,079 | 4 | -41.57% | $62.86M | |
$157,740 | 3 | 153.95% | $52.63M |
GANX Institutional Investors: Active Positions
| Increased Positions | 18 | +105.88% | 553,749 | +33.06% |
| Decreased Positions | 6 | -35.29% | 245,296 | -14.64% |
| New Positions | 10 | New | 288,677 | New |
| Sold Out Positions | 4 | Sold Out | 64,308 | Sold Out |
| Total Postitions | 29 | +70.59% | 2M | +18.41% |
GANX Ownership Change vs Market
Institutional Investor Ownership
| Dme Capital Management, Lp | $1,325.00 | 2.1% | 566,130 | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $626.00 | 0.99% | 267,421 | -4,551 | -1.67% | 2024-12-31 |
| Vanguard Group Inc | $414.00 | 0.66% | 177,075 | +31,858 | +21.94% | 2024-12-31 |
| Gotham Asset Management, Llc | $370.00 | 0.59% | 158,155 | -176,437 | -52.73% | 2024-12-31 |
| Jones Financial Companies Lllp | $230.00 | 0.36% | 98,250 | +44,750 | +83.64% | 2024-12-31 |
| Marshall Wace, Llp | $215.00 | 0.34% | 91,738 | +91,738 | New | 2024-12-31 |
| Morgan Stanley | $207.00 | 0.33% | 88,512 | +83,712 | +1,744% | 2024-12-31 |
| Blackrock, Inc. | $201.00 | 0.32% | 86,061 | +1,137 | +1.34% | 2024-12-31 |
| Northern Trust Corp | $198.00 | 0.31% | 84,586 | +39,642 | +88.2% | 2024-12-31 |
| State Street Corp | $166.00 | 0.26% | 71,137 | +36,700 | +106.57% | 2024-12-31 |